

Radiation dose intensity study in breast cancer in young women: a randomised phase III trial of additional dose to the tumour bed

Submission date 20/12/2005	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 20/12/2005	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 14/02/2019	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof H. Bartelink

Contact details
Nederlands Kanker Instituut/ Antoni van Leeuwenhoek Ziekenhuis, Plesmanlaan 121
Amsterdam
Netherlands
1166 CX
+31(0)20 512 2120/1731
h.bartelink@nki.nl

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00212121

Protocol serial number
1

Study information

Scientific Title

Radiation dose intensity study in breast cancer in young women: a randomised phase III trial of additional dose to the tumour bed

Acronym

Young Boost Trial

Study objectives

10 Gy additional boost to the tumour bed will yield an increase in local control at 10 years from 88% to 93%, with still acceptable cosmesis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Primary study design

Interventional

Study design

Randomised active-controlled phase III trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

All patients will be treated with breast conserving therapy, followed by 50 Gy to the whole breast. Patients will be randomised to receive a boost dose of 16 Gy or 26 Gy to the tumour bed.

Intervention Type

Other

Phase

Phase III

Primary outcome(s)

Local control at 10 years.

Key secondary outcome(s)

1. Cosmetic outcome
2. Additional objective is to test the genotypic and phenotypic profiles of breast tumours in young patients with invasive breast cancer, and its relation to:
 - 2.1. Local recurrence after Breast Conserving Therapy (BCT)
 - 2.2. Lymph node metastases
 - 2.3. Distant metastases and survival
 - 2.4. Radio sensitivity

2.5. Age

3. To determine whether improved genotypic and phenotypic profiles can be determined related to the endpoints mentioned in A

Completion date

01/07/2009

Eligibility

Key inclusion criteria

1. Age 50 years or younger
2. Histological diagnosis of invasive mammary cancer including all subtypes of invasive adenocarcinoma
3. Tumour location and extension imaged prior to surgery using at least mammography and ultrasound
4. Unicentric tumours and multifocal tumours removed using a wide local excision; microscopic radical resection (focally involved margins allowed, defined as: any Ductal Carcinoma In Situ [DCIS] or invasive carcinoma in three or fewer low-power fields (using a x 4 objective and a x 10 ocular lens, which has a diameter of 5 mm per low-power microscopic fields)
5. Sentinel lymph node biopsy and/or axillary lymph node dissection has been performed
6. Breast cancer stage: pT1-2pN0-2a M0
7. No treatment is allowed prior to surgery (no neoadjuvant chemotherapy, no neoadjuvant hormonal therapy, no pre-operative radiotherapy)
8. In cases where no adjuvant chemotherapy is given, wide local excision has been performed less than 10 weeks before the start of radiotherapy
9. In cases where adjuvant chemotherapy is given immediately after surgery, wide local excision has been performed less than 6 months before the start of radiotherapy, and chemotherapy should be completed less than 6 weeks before the start of radiotherapy
10. In cases where hormonal treatment is planned, this is given after completion of the radiotherapy
11. No previous history or synchronous malignant tumour in the other breast, previous history of malignant disease, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin
12. Eastern Cooperative Oncology Group (ECOG) performance scale 2 or less

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Not Specified

Key exclusion criteria

1. Residual microcalcifications on mammogram
2. All histological types of malignancies other than invasive adenocarcinoma
3. In situ carcinoma of the breast, without invasive tumour

4. Concurrent pregnancy
5. Multicentric tumours, and multifocal tumours excised using multiple excisions
6. Invasive breast cancer in both breasts

Date of first enrolment

01/07/2004

Date of final enrolment

01/07/2009

Locations

Countries of recruitment

Netherlands

Study participating centre

Nederlands Kanker Instituut/ Antoni van Leeuwenhoek Ziekenhuis, Plesmanlaan 121
Amsterdam
Netherlands
1166 CX

Sponsor information

Organisation

Commission for Clinical Applied Research (Commissie voor Klinisch Toegepast Onderzoek [CKTO]) (The Netherlands)

Funder(s)

Funder type

Research organisation

Funder Name

Commission for Clinical Applied Research (Commissie voor Klinisch Toegepast Onderzoek - CKTO) (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results	results presented at 3rd ESTRO Forum :	01/04/2015	14/02/2019	No	No
Abstract results	results presented at Clinical Science Symposium:	01/04/2018	14/02/2019	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes